Combining treatments to improve immune response in colorectal cancer
Project 1: Combinatorial adjuvants promote uniform and selective intratumoral CTL infiltration in colorectal cancer
This study is looking at a new way to help your immune system better fight colorectal cancer by using a special combination of treatments that attract immune cells to the tumor while keeping side effects low, and it's being tested to see how well it works for patients like you.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10916164 on NIH RePORTER |
What this research studies
This research investigates how a combination of specific adjuvants can enhance the infiltration of cytotoxic T lymphocytes (CTLs) into colorectal cancer tumors. By using a three-component regimen that includes TLR3 ligands and IFNα, the study aims to selectively attract immune cells to the tumor while minimizing unwanted immune responses. The approach has shown promise in preclinical models and is being evaluated in patients to determine its effectiveness in improving immune responses and patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with colorectal cancer, particularly those with liver metastases who have not responded adequately to standard treatments.
Not a fit: Patients with colorectal cancer who have contraindications to the proposed treatments or those with early-stage disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immune responses in colorectal cancer patients, potentially increasing survival rates.
How similar studies have performed: Previous studies have shown that similar approaches using immunotherapy combinations can enhance treatment efficacy, indicating a promising avenue for this research.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Kalinski, Pawel — Roswell Park Cancer Institute Corp
- Study coordinator: Kalinski, Pawel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.